Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcus Biosciences (RCUS) Operating Expenses (2017 - 2025)

Arcus Biosciences (RCUS) has 9 years of Operating Expenses data on record, last reported at $174.0 million in Q4 2025.

  • For Q4 2025, Operating Expenses changed N/A year-over-year to $174.0 million; the TTM value through Dec 2025 reached $492.0 million, changed N/A, while the annual FY2025 figure was $633.0 million, 7.65% up from the prior year.
  • Operating Expenses reached $174.0 million in Q4 2025 per RCUS's latest filing, up from $168.0 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $174.0 million in Q4 2025 and bottomed at $73.6 million in Q4 2021.
  • Average Operating Expenses over 5 years is $118.3 million, with a median of $111.5 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: skyrocketed 172.66% in 2021, then fell 6.83% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $73.6 million in 2021, then surged by 46.74% to $108.0 million in 2022, then increased by 12.96% to $122.0 million in 2023, then grew by 25.41% to $153.0 million in 2024, then grew by 13.73% to $174.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $174.0 million in Q4 2025, $168.0 million in Q3 2025, and $150.0 million in Q1 2025.